The Ultimate Guide to Codon Usage Bias & Optimization
Imagine trying to communicate with someone who speaks the same language but uses a different dialect. You both understand the words, but some phrases might [Read More…]
AbbVie and Trump Administration Announce Landmark Deal to Lower Drug Costs and Boost U.S. Investment
In a major shift for the pharmaceutical industry, AbbVie (NYSE: ABBV) announced on Monday a sweeping, voluntary agreement with the Trump administration designed to lower [Read More…]
NVIDIA and Lilly Unveil $1 Billion AI Lab to Revolutionize Drug Discovery
NVIDIA and Eli Lilly have unveiled a landmark $1 billion partnership to launch a first-of-its-kind AI co-innovation lab in the San Francisco Bay Area. By co-locating world-class scientists and AI engineers, the collaboration aims to “industrialize” drug discovery through advanced foundation models, robotics, and “lab-in-a-loop” workflows.
J&J Strikes Landmark Deal with Trump Administration to Slash Drug Prices and Boost U.S. Manufacturing
In a move that signals a significant shift in the relationship between Big Pharma and the federal government, Johnson & Johnson (NYSE: JNJ) announced a [Read More…]
Lilly to Bolster Immunology Pipeline with $1.2 Billion Acquisition of Ventyx Biosciences
Eli Lilly expands its clinical-stage portfolio with the $1.2 billion acquisition of Ventyx Biosciences, securing high-potential oral NLRP3 inhibitors to treat chronic inflammation and neurodegenerative disorders.
GSK Announces Breakthrough Phase III Results for Bepirovirsen, Signaling Potential “Functional Cure” for Chronic Hepatitis B
GSK plc (LSE/NYSE: GSK) today announced positive results from its pivotal Phase III clinical trial program for bepirovirsen. This investigational treatment could redefine the standard [Read More…]
Amgen Strengthens Oncology Pipeline with $840 Million Acquisition of Dark Blue Therapeutics
In its first major move of 2026, Amgen (NASDAQ: AMGN) has announced the acquisition of Dark Blue Therapeutics Ltd., a privately held U.K. biotech specializing [Read More…]
Novo Nordisk Launches Oral Wegovy®, Marked as First-Ever GLP-1 Weight Loss Pill Available in the U.S.
Novo Nordisk has officially launched the Wegovy® pill, the first-ever oral GLP-1 medication for weight management in adults. Following FDA approval in late 2025, this once-daily pill offers a needle-free alternative to injections, demonstrating an average weight loss of up to 17% in clinical trials. With tiered pricing starting at $149 per month for self-pay patients, oral Wegovy is now available through major U.S. pharmacies and select telehealth platforms.
Legal Landmark: Novo Nordisk Wins Final Appeal to Protect GLP-1 Innovation in China
In a significant legal victory, Novo Nordisk announced on December 31, 2025, that China’s Supreme People’s Court had issued a final, positive ruling upholding the [Read More…]
Johnson & Johnson Completes $3.05 Billion Acquisition of Halda Therapeutics to Advance Next-Gen Cancer Care
Johnson & Johnson has finalized a landmark $3.05 billion acquisition of Halda Therapeutics, integrating the clinical-stage biotech’s proprietary RIPTACâ„¢ platform. This strategic move adds HLD-0915—a next-generation oral therapy for prostate cancer to J&J’s portfolio, signaling a major shift toward precision, “cell-killing” mechanisms designed to overcome traditional treatment resistance.
